Patrick Cox

Watching this administration pretend that refusing to raise the debt ceiling is the federal government’s real problem — rather than its spending — is simply surreal.

All the major players pushing for more debt, including the president, said exactly the opposite just a few years ago. Roughly, about the time The Daily Reckoning was filming and releasing I.O.U.S.A. Back then, the current powers-that-be were criticizing the prior administration, and rightly so, when the debt was $10 trillion.

Ha. Seems laughably trite, doesn’t it?

Now, when the debt is 60% higher, the same characters are feigning outrage that anybody would take their own prior position in support of a balanced budget.

There is upside to this behavior. Certainty.

We know certain big things will happen. Whenever you know that something big is going to happen, you can make money. And that’s, after all, why you read these pages… to learn how the government and economy actually work, then plan accordingly.

We can project what’s going to happen as a result of current and past fiscal foolishness. As Herbert Stein said, “what can’t go on, won’t.” Attempts to raise taxes further will lead to lower, not greater, revenues. The cost of borrowing will go up, curtailing debt growth and forcing spending cuts.

A primary justification used by this administration for increasing spending and debt has been the expansion of health care programs. The promise of lowering health care costs has already been exposed as a pipe dream, but it has done nothing to diminish the administration’s support of these programs.

In fact, health care costs are going to go up for several reasons, including the bureaucratic burden. Additionally, people are going to live longer while more and better therapies become available. Political pressures to reduce healthcare costs will be enormous.

We’re not speculating wildly, incidentally. Costs are already exploding in places where government established national health care systems earlier, including Canada and the U.K. Rationing, known in medical circles as triage, is reality.

Information is power. If you understand this trend, you can leverage that knowledge, reducing regulatory risk and maximizing ROI by investing in emerging biotechnologies that improve and lower the costs of current medical practices. If a biotechnology does something universally accepted as necessary but does it better and for less money, you have an almost certain blockbuster.

I’ve recommended one such technology to subscribers of my Breakthrough Technology Alert. The company behind this technology has improved continual glucose monitoring with an electronically controlled device that painlessly removes the top layer of dead skin cells, the stratum corneum.

Then, a needle-free sensor measures blood sugar levels in the capillary-rich epidermis and sends that information in real-time to whatever device you choose. Instead of paying nurses to repeatedly draw blood for testing, a constant flow of information is gathered, stored and electronically displayed, eliminating human error for any reading that for some reason is out of line with actual metabolic trends.

Several studies say that continual glucose monitoring can improve hospital outcomes, mortality and length of stay by a third. Cutting hospital stays by a third in a system that pays fixed fees for specific conditions yields huge financial benefits for hospitals. It also saves hours of nursing work every day for every patient having sugars monitored.

This looks to be a breakthrough year for this tiny company, with multiple trigger events coming up soon.

Regards,

Patrick Cox
for The Daily Reckoning

Patrick Cox

Patrick Cox has lived deep inside the world of transformative technologies for over 25 years. This expertise lead him to Mauldin Economics, where he now heads Transformational Technology Alert.

  • Robert (qslv)

    It’s a great technology, but goes completely against the agenda of the powerful pharmecutical lobby. People could stabilize their blood sugar in real time with diet and exercise, losing billions in sales for the big pharma. It would be crushed.

Recent Articles

5 Min. Forecast
Bold Predictions from the Bubble Crowd

Dave Gonigam

Even if tech giants like Facebook and Apple have a down day now and then, that doesn't mean they aren't still sound companies with upside potential. Of course, some people aren't convinced... which is why the word "bubble" has now reentered the conversation. Dave Gonigam has the full story...


The Price Floor That’s Key to Gold Mining Profits

Matt Insley

Gold has had a rough go of it since the 2008 financial crisis. But according to Matt Insley, there is now a very clear price floor for the yellow metal. And what's more interesting, he comes to this conclusion by way of a glass of chocolate milk and Janet Yellen's actions from here throne at the Eccles Building. Read on...


Why You Should Tune-Out the Talk of a Tech Bubble

Paul Mampilly

The recent spate of new tech-based IPOs has a few prominent investors (Ahem... David Einhorn) touting the return of the '90s tech bubble. But there are some very good reasons why this market is nothing like the '90s, and why investors should be wary of any advice to the contrary. Paul Mampilly explains...


The Scariest Thing You Don’t Know About Generic Drugs

David Eifrig

Generic drugs are supposed to lower healthcare costs and provide you with another medical alternative. That's what it says on paper. But there's a real danger that goes along with these drugs. A danger even your doctor might not be aware of... Dr. David Eifrig has the full story. Read on...


An Unlikely Source of Dirt-Cheap Energy

Greg Guenthner

The solar panel turns 60 on Friday, but this birthday celebration will be unlike any other the industry has seen so far. In the past, solar energy's high price tag meant its wide-spread usage was nothing more than a pipe dream. But now, after six decades, solar power may finally be cheaper than oil and Asian liquefied-natural-gas. Greg Guenthner has more...